Compare PulteGroup, Inc. (PHM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs GeneDx Holdings Corp — how do they compare? PulteGroup, Inc. trades at $111.8 (market cap $21.63B), while GeneDx Holdings Corp trades at $69.42 (market cap $2.02B). The key difference: PulteGroup, Inc. is far larger — about 10.7× GeneDx Holdings Corp's market cap, and PulteGroup, Inc. pays a 0.92% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and GeneDx Holdings Corp for 19 Days on average.
| PHM | WGS | |
|---|---|---|
Market Cap | $21.63B | $2.02B |
Volume | 2,324,729 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $167.51 |
52-Week Low | $110.11 | $34.51 |
Typical Hold Time | 91 Days | 19 Days |
Enterprise Value | $22.04B | $2.05B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector weakness driven by rising mortgage rates. The stock shows bearish technical signals with key support at $110, while fundamentals reveal solid profitability with 11.62% net margin and attractive valuation at P/E of 11.6. Recent earnings show mixed results with Q2 beat but Q4 and Q1 misses, with Q3 results pending. The company maintains strong cash flow generation with $355M net cash flow in 2025.
PHM presents a value opportunity with below-market valuation and consistent profitability, though near-term headwinds from rising rates pressure housing demand. Analyst consensus targets $139.80 (24% upside) with 45% buy ratings, but technical weakness and macroeconomic risks require careful monitoring. The dividend yield provides income support during market volatility.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
